Lastly, there is an open phase II study looking at the combination of CPX-351 (liposome-encapsulated cytarabine and daunorubicin) and enasidenib in R/R AML patients with IDH2-mutations (NCT3825796). This evidence concerns the gene IDH2 and acute myeloid leukemia.